世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

FGFR阻害剤の世界市場成長 2024-2030


Global FGFR Inhibitors Market Growth 2024-2030

線維芽細胞増殖因子受容体(FGFR)阻害剤は、皮膚または内臓を覆っている組織に発生した癌(癌腫)の治療に使用される薬剤である。 FGFRは腫瘍細胞の増殖、分化、成熟に不可欠な受容体である。FGFR阻害剤はFGFR... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年7月24日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
116 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

線維芽細胞増殖因子受容体(FGFR)阻害剤は、皮膚または内臓を覆っている組織に発生した癌(癌腫)の治療に使用される薬剤である。
FGFRは腫瘍細胞の増殖、分化、成熟に不可欠な受容体である。FGFR阻害剤はFGFRに結合してその活性を阻害し、腫瘍細胞の増殖を止める。その結果、腫瘍細胞は生存できなくなり、腫瘍細胞死に至る。
世界のFGFR阻害剤市場規模は、2024年の百万米ドルから2030年には百万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は%と予測されている。
LPインフォメーション社の最新調査レポート「FGFR阻害剤産業予測」は、2023年のFGFR阻害剤の過去の売上高と世界全体の売上高に注目し、2024年から2030年までのFGFR阻害剤の売上高予測について地域別・市場分野別に包括的に分析しています。FGFR阻害剤の売上高を地域別、市場セクター別、サブセクター別に分類し、世界のFGFR阻害剤産業の詳細な分析を百万米ドル単位で提供しています。
本インサイトレポートでは、世界のFGFR阻害剤の状況を包括的に分析し、製品区分、企業形成、収益、市場シェア、最新開発、M&A活動に関する主要動向を明らかにしています。また、本レポートでは、FGFR阻害剤のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、主要グローバル企業の戦略を分析し、加速する世界のFGFR阻害剤市場におけるこれらの企業の独自の地位をより良く理解しています。
本インサイトレポートでは、FGFR阻害剤の世界的な見通しを形成している主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に分けて予測を行い、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界のFGFR阻害剤の現状と将来の軌道について非常にニュアンスのある見解を提供します。
FGFR阻害剤の米国市場は、2023年の百万米ドルから2030年には百万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。
FGFR阻害剤の中国市場は、2023年の百万米ドルから2030年には百万米ドルに、2024年から2030年までの年平均成長率は%と推定される。
FGFR阻害剤の欧州市場は、2023年の百万米ドルから2030年には百万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。
FGFR阻害剤の世界的な主要企業は、ヤンセン(ジョンソン・エンド・ジョンソン)、Incyte Corporation、Taiho Oncology、QED Therapeutics(BridgeBio)、Bayerなどである。売上高では、世界の2大企業が2023年にほぼ100%のシェアを占めている。
のシェアを占めています。
当レポートでは、FGFR阻害剤市場の製品タイプ別、用途別、主要メーカー別、主要地域・国別の包括的な概要、市場シェア、成長機会を紹介しています。
タイプ別セグメンテーション
汎FGFR阻害剤
選択的FGFR阻害剤
用途別セグメンテーション
胆管癌
尿路上皮がん
本レポートはまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、一次専門家から収集したインプットと、企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ヤンセン(ジョンソン・エンド・ジョンソン)
インサイト社
タイホー・オンコロジー
QEDセラピューティクス(ブリッジバイオ)
バイエル
エーザイ
ブループリント医薬品
デビオファーム
アビスコ・セラピューティクス
イノケア
CStone
エベレスト医薬品
ベタ・ファーマシューティカルズ
本レポートで扱う主な質問
世界のFGFR阻害剤市場の10年見通しは?
FGFR阻害剤の世界市場および地域別市場成長の要因は何か?
市場別、地域別に最も急成長する技術は何か?
FGFR阻害剤の市場機会は最終市場規模によってどのように異なるのか?
FGFR阻害剤のタイプ別、用途別の内訳は?



ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global FGFR Inhibitors Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for FGFR Inhibitors by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for FGFR Inhibitors by Country/Region, 2019, 2023 & 2030
2.2 FGFR Inhibitors Segment by Type
2.2.1 Pan-FGFR Inhibitors
2.2.2 Selective FGFR Inhibitors
2.3 FGFR Inhibitors Sales by Type
2.3.1 Global FGFR Inhibitors Sales Market Share by Type (2019-2024)
2.3.2 Global FGFR Inhibitors Revenue and Market Share by Type (2019-2024)
2.3.3 Global FGFR Inhibitors Sale Price by Type (2019-2024)
2.4 FGFR Inhibitors Segment by Application
2.4.1 Cholangiocarcinoma
2.4.2 Urothelial Carcinoma
2.5 FGFR Inhibitors Sales by Application
2.5.1 Global FGFR Inhibitors Sale Market Share by Application (2019-2024)
2.5.2 Global FGFR Inhibitors Revenue and Market Share by Application (2019-2024)
2.5.3 Global FGFR Inhibitors Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global FGFR Inhibitors Breakdown Data by Company
3.1.1 Global FGFR Inhibitors Annual Sales by Company (2019-2024)
3.1.2 Global FGFR Inhibitors Sales Market Share by Company (2019-2024)
3.2 Global FGFR Inhibitors Annual Revenue by Company (2019-2024)
3.2.1 Global FGFR Inhibitors Revenue by Company (2019-2024)
3.2.2 Global FGFR Inhibitors Revenue Market Share by Company (2019-2024)
3.3 Global FGFR Inhibitors Sale Price by Company
3.4 Key Manufacturers FGFR Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers FGFR Inhibitors Product Location Distribution
3.4.2 Players FGFR Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for FGFR Inhibitors by Geographic Region
4.1 World Historic FGFR Inhibitors Market Size by Geographic Region (2019-2024)
4.1.1 Global FGFR Inhibitors Annual Sales by Geographic Region (2019-2024)
4.1.2 Global FGFR Inhibitors Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic FGFR Inhibitors Market Size by Country/Region (2019-2024)
4.2.1 Global FGFR Inhibitors Annual Sales by Country/Region (2019-2024)
4.2.2 Global FGFR Inhibitors Annual Revenue by Country/Region (2019-2024)
4.3 Americas FGFR Inhibitors Sales Growth
4.4 APAC FGFR Inhibitors Sales Growth
4.5 Europe FGFR Inhibitors Sales Growth
4.6 Middle East & Africa FGFR Inhibitors Sales Growth
5 Americas
5.1 Americas FGFR Inhibitors Sales by Country
5.1.1 Americas FGFR Inhibitors Sales by Country (2019-2024)
5.1.2 Americas FGFR Inhibitors Revenue by Country (2019-2024)
5.2 Americas FGFR Inhibitors Sales by Type (2019-2024)
5.3 Americas FGFR Inhibitors Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC FGFR Inhibitors Sales by Region
6.1.1 APAC FGFR Inhibitors Sales by Region (2019-2024)
6.1.2 APAC FGFR Inhibitors Revenue by Region (2019-2024)
6.2 APAC FGFR Inhibitors Sales by Type (2019-2024)
6.3 APAC FGFR Inhibitors Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe FGFR Inhibitors by Country
7.1.1 Europe FGFR Inhibitors Sales by Country (2019-2024)
7.1.2 Europe FGFR Inhibitors Revenue by Country (2019-2024)
7.2 Europe FGFR Inhibitors Sales by Type (2019-2024)
7.3 Europe FGFR Inhibitors Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa FGFR Inhibitors by Country
8.1.1 Middle East & Africa FGFR Inhibitors Sales by Country (2019-2024)
8.1.2 Middle East & Africa FGFR Inhibitors Revenue by Country (2019-2024)
8.2 Middle East & Africa FGFR Inhibitors Sales by Type (2019-2024)
8.3 Middle East & Africa FGFR Inhibitors Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of FGFR Inhibitors
10.3 Manufacturing Process Analysis of FGFR Inhibitors
10.4 Industry Chain Structure of FGFR Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 FGFR Inhibitors Distributors
11.3 FGFR Inhibitors Customer
12 World Forecast Review for FGFR Inhibitors by Geographic Region
12.1 Global FGFR Inhibitors Market Size Forecast by Region
12.1.1 Global FGFR Inhibitors Forecast by Region (2025-2030)
12.1.2 Global FGFR Inhibitors Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global FGFR Inhibitors Forecast by Type (2025-2030)
12.7 Global FGFR Inhibitors Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Janssen (Johnson & Johnson)
13.1.1 Janssen (Johnson & Johnson) Company Information
13.1.2 Janssen (Johnson & Johnson) FGFR Inhibitors Product Portfolios and Specifications
13.1.3 Janssen (Johnson & Johnson) FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Janssen (Johnson & Johnson) Main Business Overview
13.1.5 Janssen (Johnson & Johnson) Latest Developments
13.2 Incyte Corporation
13.2.1 Incyte Corporation Company Information
13.2.2 Incyte Corporation FGFR Inhibitors Product Portfolios and Specifications
13.2.3 Incyte Corporation FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Incyte Corporation Main Business Overview
13.2.5 Incyte Corporation Latest Developments
13.3 Taiho Oncology
13.3.1 Taiho Oncology Company Information
13.3.2 Taiho Oncology FGFR Inhibitors Product Portfolios and Specifications
13.3.3 Taiho Oncology FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Taiho Oncology Main Business Overview
13.3.5 Taiho Oncology Latest Developments
13.4 QED Therapeutics (BridgeBio)
13.4.1 QED Therapeutics (BridgeBio) Company Information
13.4.2 QED Therapeutics (BridgeBio) FGFR Inhibitors Product Portfolios and Specifications
13.4.3 QED Therapeutics (BridgeBio) FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 QED Therapeutics (BridgeBio) Main Business Overview
13.4.5 QED Therapeutics (BridgeBio) Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer FGFR Inhibitors Product Portfolios and Specifications
13.5.3 Bayer FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Eisai
13.6.1 Eisai Company Information
13.6.2 Eisai FGFR Inhibitors Product Portfolios and Specifications
13.6.3 Eisai FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Eisai Main Business Overview
13.6.5 Eisai Latest Developments
13.7 Blueprint Medicines
13.7.1 Blueprint Medicines Company Information
13.7.2 Blueprint Medicines FGFR Inhibitors Product Portfolios and Specifications
13.7.3 Blueprint Medicines FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Blueprint Medicines Main Business Overview
13.7.5 Blueprint Medicines Latest Developments
13.8 Debiopharm
13.8.1 Debiopharm Company Information
13.8.2 Debiopharm FGFR Inhibitors Product Portfolios and Specifications
13.8.3 Debiopharm FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Debiopharm Main Business Overview
13.8.5 Debiopharm Latest Developments
13.9 Abbisko Therapeutics
13.9.1 Abbisko Therapeutics Company Information
13.9.2 Abbisko Therapeutics FGFR Inhibitors Product Portfolios and Specifications
13.9.3 Abbisko Therapeutics FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Abbisko Therapeutics Main Business Overview
13.9.5 Abbisko Therapeutics Latest Developments
13.10 InnoCare
13.10.1 InnoCare Company Information
13.10.2 InnoCare FGFR Inhibitors Product Portfolios and Specifications
13.10.3 InnoCare FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 InnoCare Main Business Overview
13.10.5 InnoCare Latest Developments
13.11 CStone
13.11.1 CStone Company Information
13.11.2 CStone FGFR Inhibitors Product Portfolios and Specifications
13.11.3 CStone FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 CStone Main Business Overview
13.11.5 CStone Latest Developments
13.12 Everest Medicines
13.12.1 Everest Medicines Company Information
13.12.2 Everest Medicines FGFR Inhibitors Product Portfolios and Specifications
13.12.3 Everest Medicines FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Everest Medicines Main Business Overview
13.12.5 Everest Medicines Latest Developments
13.13 Betta Pharmaceuticals
13.13.1 Betta Pharmaceuticals Company Information
13.13.2 Betta Pharmaceuticals FGFR Inhibitors Product Portfolios and Specifications
13.13.3 Betta Pharmaceuticals FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Betta Pharmaceuticals Main Business Overview
13.13.5 Betta Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

Fibroblast growth factor receptor (FGFR) inhibitors are drugs used for treating cancer that originates in the skin or in tissues that line or cover internal organs (carcinoma).
FGFR is a receptor essential for the growth, differentiation, and maturation of a tumor cell. FGFR inhibitors bind to FGFRs and prevent their activity, thereby stopping tumor cell growth. As a result, the tumor cells fail to survive, leading to tumor cell death.
The global FGFR Inhibitors market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “FGFR Inhibitors Industry Forecast” looks at past sales and reviews total world FGFR Inhibitors sales in 2023, providing a comprehensive analysis by region and market sector of projected FGFR Inhibitors sales for 2024 through 2030. With FGFR Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world FGFR Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global FGFR Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on FGFR Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global FGFR Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for FGFR Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global FGFR Inhibitors.
United States market for FGFR Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for FGFR Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for FGFR Inhibitors is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key FGFR Inhibitors players cover Janssen (Johnson & Johnson), Incyte Corporation, Taiho Oncology, QED Therapeutics (BridgeBio), Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of FGFR Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Pan-FGFR Inhibitors
Selective FGFR Inhibitors
Segmentation by Application:
Cholangiocarcinoma
Urothelial Carcinoma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Janssen (Johnson & Johnson)
Incyte Corporation
Taiho Oncology
QED Therapeutics (BridgeBio)
Bayer
Eisai
Blueprint Medicines
Debiopharm
Abbisko Therapeutics
InnoCare
CStone
Everest Medicines
Betta Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global FGFR Inhibitors market?
What factors are driving FGFR Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do FGFR Inhibitors market opportunities vary by end market size?
How does FGFR Inhibitors break out by Type, by Application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global FGFR Inhibitors Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for FGFR Inhibitors by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for FGFR Inhibitors by Country/Region, 2019, 2023 & 2030
2.2 FGFR Inhibitors Segment by Type
2.2.1 Pan-FGFR Inhibitors
2.2.2 Selective FGFR Inhibitors
2.3 FGFR Inhibitors Sales by Type
2.3.1 Global FGFR Inhibitors Sales Market Share by Type (2019-2024)
2.3.2 Global FGFR Inhibitors Revenue and Market Share by Type (2019-2024)
2.3.3 Global FGFR Inhibitors Sale Price by Type (2019-2024)
2.4 FGFR Inhibitors Segment by Application
2.4.1 Cholangiocarcinoma
2.4.2 Urothelial Carcinoma
2.5 FGFR Inhibitors Sales by Application
2.5.1 Global FGFR Inhibitors Sale Market Share by Application (2019-2024)
2.5.2 Global FGFR Inhibitors Revenue and Market Share by Application (2019-2024)
2.5.3 Global FGFR Inhibitors Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global FGFR Inhibitors Breakdown Data by Company
3.1.1 Global FGFR Inhibitors Annual Sales by Company (2019-2024)
3.1.2 Global FGFR Inhibitors Sales Market Share by Company (2019-2024)
3.2 Global FGFR Inhibitors Annual Revenue by Company (2019-2024)
3.2.1 Global FGFR Inhibitors Revenue by Company (2019-2024)
3.2.2 Global FGFR Inhibitors Revenue Market Share by Company (2019-2024)
3.3 Global FGFR Inhibitors Sale Price by Company
3.4 Key Manufacturers FGFR Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers FGFR Inhibitors Product Location Distribution
3.4.2 Players FGFR Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for FGFR Inhibitors by Geographic Region
4.1 World Historic FGFR Inhibitors Market Size by Geographic Region (2019-2024)
4.1.1 Global FGFR Inhibitors Annual Sales by Geographic Region (2019-2024)
4.1.2 Global FGFR Inhibitors Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic FGFR Inhibitors Market Size by Country/Region (2019-2024)
4.2.1 Global FGFR Inhibitors Annual Sales by Country/Region (2019-2024)
4.2.2 Global FGFR Inhibitors Annual Revenue by Country/Region (2019-2024)
4.3 Americas FGFR Inhibitors Sales Growth
4.4 APAC FGFR Inhibitors Sales Growth
4.5 Europe FGFR Inhibitors Sales Growth
4.6 Middle East & Africa FGFR Inhibitors Sales Growth
5 Americas
5.1 Americas FGFR Inhibitors Sales by Country
5.1.1 Americas FGFR Inhibitors Sales by Country (2019-2024)
5.1.2 Americas FGFR Inhibitors Revenue by Country (2019-2024)
5.2 Americas FGFR Inhibitors Sales by Type (2019-2024)
5.3 Americas FGFR Inhibitors Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC FGFR Inhibitors Sales by Region
6.1.1 APAC FGFR Inhibitors Sales by Region (2019-2024)
6.1.2 APAC FGFR Inhibitors Revenue by Region (2019-2024)
6.2 APAC FGFR Inhibitors Sales by Type (2019-2024)
6.3 APAC FGFR Inhibitors Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe FGFR Inhibitors by Country
7.1.1 Europe FGFR Inhibitors Sales by Country (2019-2024)
7.1.2 Europe FGFR Inhibitors Revenue by Country (2019-2024)
7.2 Europe FGFR Inhibitors Sales by Type (2019-2024)
7.3 Europe FGFR Inhibitors Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa FGFR Inhibitors by Country
8.1.1 Middle East & Africa FGFR Inhibitors Sales by Country (2019-2024)
8.1.2 Middle East & Africa FGFR Inhibitors Revenue by Country (2019-2024)
8.2 Middle East & Africa FGFR Inhibitors Sales by Type (2019-2024)
8.3 Middle East & Africa FGFR Inhibitors Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of FGFR Inhibitors
10.3 Manufacturing Process Analysis of FGFR Inhibitors
10.4 Industry Chain Structure of FGFR Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 FGFR Inhibitors Distributors
11.3 FGFR Inhibitors Customer
12 World Forecast Review for FGFR Inhibitors by Geographic Region
12.1 Global FGFR Inhibitors Market Size Forecast by Region
12.1.1 Global FGFR Inhibitors Forecast by Region (2025-2030)
12.1.2 Global FGFR Inhibitors Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global FGFR Inhibitors Forecast by Type (2025-2030)
12.7 Global FGFR Inhibitors Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Janssen (Johnson & Johnson)
13.1.1 Janssen (Johnson & Johnson) Company Information
13.1.2 Janssen (Johnson & Johnson) FGFR Inhibitors Product Portfolios and Specifications
13.1.3 Janssen (Johnson & Johnson) FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Janssen (Johnson & Johnson) Main Business Overview
13.1.5 Janssen (Johnson & Johnson) Latest Developments
13.2 Incyte Corporation
13.2.1 Incyte Corporation Company Information
13.2.2 Incyte Corporation FGFR Inhibitors Product Portfolios and Specifications
13.2.3 Incyte Corporation FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Incyte Corporation Main Business Overview
13.2.5 Incyte Corporation Latest Developments
13.3 Taiho Oncology
13.3.1 Taiho Oncology Company Information
13.3.2 Taiho Oncology FGFR Inhibitors Product Portfolios and Specifications
13.3.3 Taiho Oncology FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Taiho Oncology Main Business Overview
13.3.5 Taiho Oncology Latest Developments
13.4 QED Therapeutics (BridgeBio)
13.4.1 QED Therapeutics (BridgeBio) Company Information
13.4.2 QED Therapeutics (BridgeBio) FGFR Inhibitors Product Portfolios and Specifications
13.4.3 QED Therapeutics (BridgeBio) FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 QED Therapeutics (BridgeBio) Main Business Overview
13.4.5 QED Therapeutics (BridgeBio) Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer FGFR Inhibitors Product Portfolios and Specifications
13.5.3 Bayer FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Eisai
13.6.1 Eisai Company Information
13.6.2 Eisai FGFR Inhibitors Product Portfolios and Specifications
13.6.3 Eisai FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Eisai Main Business Overview
13.6.5 Eisai Latest Developments
13.7 Blueprint Medicines
13.7.1 Blueprint Medicines Company Information
13.7.2 Blueprint Medicines FGFR Inhibitors Product Portfolios and Specifications
13.7.3 Blueprint Medicines FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Blueprint Medicines Main Business Overview
13.7.5 Blueprint Medicines Latest Developments
13.8 Debiopharm
13.8.1 Debiopharm Company Information
13.8.2 Debiopharm FGFR Inhibitors Product Portfolios and Specifications
13.8.3 Debiopharm FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Debiopharm Main Business Overview
13.8.5 Debiopharm Latest Developments
13.9 Abbisko Therapeutics
13.9.1 Abbisko Therapeutics Company Information
13.9.2 Abbisko Therapeutics FGFR Inhibitors Product Portfolios and Specifications
13.9.3 Abbisko Therapeutics FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Abbisko Therapeutics Main Business Overview
13.9.5 Abbisko Therapeutics Latest Developments
13.10 InnoCare
13.10.1 InnoCare Company Information
13.10.2 InnoCare FGFR Inhibitors Product Portfolios and Specifications
13.10.3 InnoCare FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 InnoCare Main Business Overview
13.10.5 InnoCare Latest Developments
13.11 CStone
13.11.1 CStone Company Information
13.11.2 CStone FGFR Inhibitors Product Portfolios and Specifications
13.11.3 CStone FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 CStone Main Business Overview
13.11.5 CStone Latest Developments
13.12 Everest Medicines
13.12.1 Everest Medicines Company Information
13.12.2 Everest Medicines FGFR Inhibitors Product Portfolios and Specifications
13.12.3 Everest Medicines FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Everest Medicines Main Business Overview
13.12.5 Everest Medicines Latest Developments
13.13 Betta Pharmaceuticals
13.13.1 Betta Pharmaceuticals Company Information
13.13.2 Betta Pharmaceuticals FGFR Inhibitors Product Portfolios and Specifications
13.13.3 Betta Pharmaceuticals FGFR Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Betta Pharmaceuticals Main Business Overview
13.13.5 Betta Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(inhibitors)の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る